PRX1 Antibody

What is PRX1/PRRX1 and why is it significant for research?

PRX1 (also known as PRRX1) is a paired related homeobox 1 transcription factor in humans. It may also be referred to as AGOTC, PHOX1, PMX1, PRX-1, paired mesoderm homeobox protein 1, or homeobox protein PHOX1. The protein has a molecular weight of approximately 27.3 kilodaltons . PRX1/PRRX1 plays crucial roles in embryonic development, particularly in mesenchymal cell differentiation, and has been implicated in cancer progression including breast, prostate, and lung cancers . Its function in promoting pulmonary endothelial cell (EC) differentiation within fetal lung mesoderm and subsequent incorporation into vascular networks makes it a significant target for developmental biology research .

What applications are most suitable for PRX1/PRRX1 antibodies?

Based on commercially available antibodies, PRX1/PRRX1 antibodies have been validated for multiple applications:

Different suppliers offer antibodies optimized for specific applications, so researchers should select products based on their experimental needs .

What species reactivity should be considered when selecting a PRX1/PRRX1 antibody?

When selecting PRX1/PRRX1 antibodies, consider these species reactivity patterns:

Always verify that the antibody has been validated for your specific species of interest through techniques appropriate for your application .

How can I investigate PRX1/PRRX1's role in pulmonary vascular development?

For researching PRX1/PRRX1's role in pulmonary vascular development, implement the following methodological approach:

• Knockout model analysis: Compare wild-type and Prx1 −/− mouse lungs through:

  • RT-PCR to assess expression levels of Flk-1 and VCAM-1 mRNAs

  • Immunohistochemistry to quantify vWF-positive blood vessels

  • Gene microarray analysis to identify other affected EC-specific genes

• Cellular morphology assessment: Establish stable cell lines expressing PRX1/PRRX1 (using vectors like Prx1-HA) and analyze:

  • Cell morphology changes using microscopy

  • EC marker expression (PECAM-1, vWF, VE-cadherin) via FACs analysis and Western immunoblotting

• Network formation analysis: Evaluate vascular network formation through:

  • Culture of PRX1/PRRX1-expressing cells on Matrigel

  • Immunostaining for TN-C protein deposition around developing networks

  • Laser confocal microscopy to quantify TN-C synthesis and deposition

These methodologies provide complementary insights into PRX1/PRRX1's functional role in vascular development.

What controls are essential for validating PRX1/PRRX1 antibody specificity?

To ensure antibody specificity and reliable results, implement these essential controls:

• Expression verification controls:

  • Positive control: Use cell lines known to express PRX1/PRRX1 (e.g., HeLa cells)

  • Negative control: Include samples known not to express the target protein

  • Genetic validation: Compare wild-type vs. Prx1 −/− tissues

• Technical controls:

  • Primary antibody omission: Perform all protocol steps without primary antibody

  • Isotype control: Use control IgG of the same species/isotype

  • Peptide competition: Pre-incubate antibody with immunogen peptide

• Expression system controls:

  • Verify recombinant protein expression using tag-specific antibodies (e.g., anti-HA for Prx1-HA fusion proteins)

  • Compare multiple antibodies targeting different epitopes of PRX1/PRRX1

• Dilution optimization:

  • Test recommended dilution ranges (e.g., 1:500-1:1000 for WB)

  • Document optimal signal-to-noise ratios

These controls address the antibody characterization concerns highlighted in recent literature and enhance experimental reproducibility .

How should I approach studying the relationship between PRX1/PRRX1 and TN-C?

Research has established that PRX1/PRRX1 regulates TN-C expression, which is critical for vascular network formation. To investigate this relationship:

• Expression correlation studies:

  • RT-PCR analysis of TN-C mRNA levels in wild-type vs. Prx1 −/− mouse lungs

  • Immunohistochemical comparison of TN-C protein expression in these tissues

• Temporal expression analysis:

  • Examine TN-C synthesis in PRX1/PRRX1-expressing cells on Matrigel at early timepoints (1 hour)

  • Track TN-C deposition around developing vascular networks at later timepoints (3 hours)

• Visualization techniques:

  • Use laser confocal microscopy to quantify TN-C protein synthesis

  • Perform immunostaining to visualize how vascular networks become enveloped by extracellular TN-C protein

This methodological approach provides insights into both the regulatory relationship and functional significance of PRX1/PRRX1-mediated TN-C expression.

What are common troubleshooting strategies for Western blot detection of PRX1/PRRX1?

When encountering issues with Western blot detection of PRX1/PRRX1, consider these application-specific solutions:

Additionally, ensure that you're using appropriate lysis buffers and protein extraction methods that preserve the structural integrity of nuclear transcription factors like PRX1/PRRX1.

How can I optimize immunohistochemistry protocols for PRX1/PRRX1 detection?

For optimal immunohistochemical detection of PRX1/PRRX1 in tissue sections:

• Fixation optimization:

  • Compare multiple fixatives to determine optimal epitope preservation

  • Adjust fixation duration based on tissue type and thickness

• Antigen retrieval:

  • Test both heat-induced and enzymatic retrieval methods

  • Optimize pH of retrieval buffers (citrate vs. EDTA-based)

• Blocking parameters:

  • Use species-appropriate serum or protein blockers

  • Include additional blocking steps if nonspecific binding occurs

• Antibody parameters:

  • Optimize primary antibody concentration through titration

  • Extend primary antibody incubation (overnight at 4°C)

  • Select detection systems appropriate for tissue type

• Validation approaches:

  • Include known positive tissues alongside experimental samples

  • Use control IgG to verify staining specificity

  • Compare staining patterns with published literature

These optimization steps address the variability in antibody performance highlighted in antibody characterization literature .

What factors should I consider when selecting between polyclonal and monoclonal anti-PRX1/PRRX1 antibodies?

The choice between polyclonal and monoclonal antibodies depends on your specific application:

For developmental studies examining PRX1/PRRX1's role in vascular formation, consider how epitope accessibility might be affected by protein interactions or conformational changes in different contexts .

How should I design experiments to study PRX1/PRRX1's role in cancer progression?

For investigating PRX1/PRRX1 in cancer progression, implement this experimental framework:

• Expression analysis in clinical samples:

  • Compare PRX1/PRRX1 expression across cancer stages and types

  • Correlate expression with patient outcomes and clinical parameters

  • Use validated antibodies for IHC on tissue microarrays

• Functional studies in cell models:

  • Establish stable cell lines with PRX1/PRRX1 overexpression (using vectors like Prx1-HA)

  • Create knockdown/knockout models using siRNA or CRISPR-Cas9

  • Verify expression changes via Western blot (1:500-1:1000 dilution)

• Phenotypic assays:

  • Assess changes in cell morphology (as observed in RFL-6 cells)

  • Evaluate proliferation, migration, and invasion capacity

  • Analyze EMT marker expression given PRX1/PRRX1's role in mesenchymal differentiation

• Molecular mechanism investigation:

  • Examine downstream target gene expression (such as TN-C)

  • Analyze pathway activation through phosphorylation studies

  • Perform co-immunoprecipitation to identify interaction partners

This comprehensive approach enables both correlative and causative insights into PRX1/PRRX1's function in cancer.

What considerations are important when interpreting developmental expression patterns of PRX1/PRRX1?

When analyzing developmental expression patterns:

• Spatiotemporal resolution:

  • Document precise developmental stages examined

  • Compare expression across multiple tissue types

  • Consider expression in relation to critical developmental windows

• Marker co-expression analysis:

  • Evaluate correlation with endothelial markers (PECAM-1, vWF, VE-cadherin)

  • Assess relationship with angiogenic regulators (Flk-1, VCAM-1)

  • Examine extracellular matrix protein expression (TN-C)

• Functional correlation:

  • Link expression patterns to specific developmental processes

  • Compare wild-type vs. knockout phenotypes (e.g., vascular network formation)

  • Assess consequences of expression disruption (respiratory distress, vascular defects)

• Quantitative assessment:

  • Use standardized quantification methods for comparing expression levels

  • Normalize data appropriately across developmental timepoints

  • Apply statistical analyses to identify significant expression changes

These considerations enable more accurate interpretation of PRX1/PRRX1's developmental roles.

How can I approach antibody validation to address reproducibility concerns?

To address the "antibody characterization crisis" highlighted in recent literature , implement this comprehensive validation strategy:

• Specificity verification:

  • Test in knockout/knockdown systems (e.g., Prx1 −/− tissues)

  • Perform peptide competition assays

  • Compare multiple antibodies targeting different epitopes

  • Verify detection of recombinant protein standards

• Application-specific validation:

  • Validate for each distinct application (WB, IHC, IF, etc.)

  • Document optimal conditions and protocol parameters

  • Include positive controls (e.g., HeLa cells)

  • Use appropriate negative controls (control IgG)

• Cross-reactivity assessment:

  • Test in multiple species if cross-reactivity is claimed

  • Evaluate potential cross-reactivity with related homeobox proteins

  • Confirm specificity via orthogonal methods (mRNA analysis)

• Documentation and transparency:

  • Report complete validation methodologies in publications

  • Document antibody source, catalog number, and lot information

  • Share validation data through repositories or supplementary materials

This rigorous validation approach aligns with recommendations from scientific societies and funders to increase research reproducibility .

What emerging applications of PRX1/PRRX1 antibodies show promise for advancing research?

Emerging applications for PRX1/PRRX1 antibodies include:

• Single-cell analysis techniques:

  • Mass cytometry (CyTOF) for high-dimensional protein analysis

  • Imaging mass cytometry for spatial protein detection

  • Single-cell Western blotting for heterogeneity assessment

• Advanced imaging applications:

  • Super-resolution microscopy for nanoscale localization

  • Intravital imaging for in vivo dynamics

  • Multiplexed immunofluorescence for co-expression analysis

• Therapeutic development support:

  • Biomarker validation for cancer diagnostics

  • Patient stratification for personalized medicine

  • Treatment response monitoring

• Technological integration:

  • Antibody-based biosensors for real-time detection

  • CRISPR screening validation

  • Spatial transcriptomics correlation

These applications will expand our understanding of PRX1/PRRX1's functional roles in development and disease.